These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38204163)

  • 21. Synthesis of GalNAc-Oligonucleotide Conjugates Using GalNAc Phosphoramidite and Triple-GalNAc CPG Solid Support.
    Ulashchik EA; Martynenko-Makaev YV; Akhlamionok TP; Melnik DM; Shmanai VV; Zatsepin TS
    Methods Mol Biol; 2021; 2282():101-118. PubMed ID: 33928572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.
    Springer AD; Dowdy SF
    Nucleic Acid Ther; 2018 Jun; 28(3):109-118. PubMed ID: 29792572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.
    Østergaard ME; Yu J; Kinberger GA; Wan WB; Migawa MT; Vasquez G; Schmidt K; Gaus HJ; Murray HM; Low A; Swayze EE; Prakash TP; Seth PP
    Bioconjug Chem; 2015 Aug; 26(8):1451-5. PubMed ID: 26011654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.
    Brown CR; Gupta S; Qin J; Racie T; He G; Lentini S; Malone R; Yu M; Matsuda S; Shulga-Morskaya S; Nair AV; Theile CS; Schmidt K; Shahraz A; Goel V; Parmar RG; Zlatev I; Schlegel MK; Nair JK; Jayaraman M; Manoharan M; Brown D; Maier MA; Jadhav V
    Nucleic Acids Res; 2020 Dec; 48(21):11827-11844. PubMed ID: 32808038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonuclease.
    Kumar P; Degaonkar R; Guenther DC; Abramov M; Schepers G; Capobianco M; Jiang Y; Harp J; Kaittanis C; Janas MM; Castoreno A; Zlatev I; Schlegel MK; Herdewijn P; Egli M; Manoharan M
    Nucleic Acids Res; 2020 May; 48(8):4028-4040. PubMed ID: 32170309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity.
    Janas MM; Schlegel MK; Harbison CE; Yilmaz VO; Jiang Y; Parmar R; Zlatev I; Castoreno A; Xu H; Shulga-Morskaya S; Rajeev KG; Manoharan M; Keirstead ND; Maier MA; Jadhav V
    Nat Commun; 2018 Feb; 9(1):723. PubMed ID: 29459660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of Monovalent N-Acetylgalactosamine Phosphoramidite for Liver-Targeting Oligonucleotides.
    Yamamoto T; Terada C; Kashiwada K; Yamayoshi A; Harada-Shiba M; Obika S
    Curr Protoc Nucleic Acid Chem; 2019 Sep; 78(1):e99. PubMed ID: 31529782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.
    Janas MM; Zlatev I; Liu J; Jiang Y; Barros SA; Sutherland JE; Davis WP; Liu J; Brown CR; Liu X; Schlegel MK; Blair L; Zhang X; Das B; Tran C; Aluri K; Li J; Agarwal S; Indrakanti R; Charisse K; Nair J; Matsuda S; Rajeev KG; Zimmermann T; Sepp-Lorenzino L; Xu Y; Akinc A; Fitzgerald K; Vaishnaw AK; Smith PF; Manoharan M; Jadhav V; Wu JT; Maier MA
    Nucleic Acids Res; 2019 Apr; 47(7):3306-3320. PubMed ID: 30820542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Automated Solid-Phase Click Synthesis of Oligonucleotide Conjugates: From Small Molecules to Diverse N-Acetylgalactosamine Clusters.
    Farzan VM; Ulashchik EA; Martynenko-Makaev YV; Kvach MV; Aparin IO; Brylev VA; Prikazchikova TA; Maklakova SY; Majouga AG; Ustinov AV; Shipulin GA; Shmanai VV; Korshun VA; Zatsepin TS
    Bioconjug Chem; 2017 Oct; 28(10):2599-2607. PubMed ID: 28921968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand conjugate SAR and enhanced delivery in NHP.
    Holland RJ; Lam K; Ye X; Martin AD; Wood MC; Palmer L; Fraser D; McClintock K; Majeski S; Jarosz A; Lee ACH; Thi EP; Judge A; Heyes J
    Mol Ther; 2021 Oct; 29(10):2910-2919. PubMed ID: 34091052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5'-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates.
    Parmar R; Willoughby JL; Liu J; Foster DJ; Brigham B; Theile CS; Charisse K; Akinc A; Guidry E; Pei Y; Strapps W; Cancilla M; Stanton MG; Rajeev KG; Sepp-Lorenzino L; Manoharan M; Meyers R; Maier MA; Jadhav V
    Chembiochem; 2016 Jun; 17(11):985-9. PubMed ID: 27121751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver cancer cells as the model for developing liver-targeted RNAi therapeutics.
    Hou B; Qin L; Huang L
    Biochem Biophys Res Commun; 2023 Feb; 644():85-94. PubMed ID: 36640667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease.
    He X; Chang Z; Chen F; Zhang W; Sun M; Shi T; Liu J; Chen P; Zhang K; Guan S; Zhao Z; Li M; Dong WF; Shao D; Yang C
    Acta Biomater; 2024 Jan; 174():281-296. PubMed ID: 37951519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged cultured human hepatocytes as an in vitro experimental system for the evaluation of potency and duration of activity of RNA therapeutics: Demonstration of prolonged duration of gene silencing effects of a GalNAc-conjugated human hypoxanthine phosphoribosyl transferase (HPRT1) siRNA.
    Yang Q; Humphreys SC; Lade JM; Li AP
    Biochem Pharmacol; 2021 Jul; 189():114374. PubMed ID: 33358826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease.
    Rider D; Chivers S; Aretz J; Eisermann M; Löffler K; Hauptmann J; Morrison E; Campion G
    Toxicol Sci; 2022 Sep; 189(2):237-249. PubMed ID: 35737426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies.
    Cedillo I; Chreng D; Engle E; Chen L; McPherson AK; Rodriguez AA
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28809818
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Lu J; Swearingen E; Hardy M; Collins P; Wu B; Yuan E; Lu D; Li CM; Wang S; Ollmann M
    Mol Ther Nucleic Acids; 2022 Jun; 28():423-434. PubMed ID: 35505960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection.
    Ye X; Holland R; Wood M; Pasetka C; Palmer L; Samaridou E; McClintock K; Borisevich V; Geisbert TW; Cross RW; Heyes J
    Mol Ther; 2023 Jan; 31(1):269-281. PubMed ID: 36114672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs.
    Schlegel MK; Matsuda S; Brown CR; Harp JM; Barry JD; Berman D; Castoreno A; Schofield S; Szeto J; Manoharan M; Charissé K; Egli M; Maier MA
    Nucleic Acids Res; 2021 Nov; 49(19):10851-10867. PubMed ID: 34648028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.
    Janas MM; Harbison CE; Perry VK; Carito B; Sutherland JE; Vaishnaw AK; Keirstead ND; Warner G
    Toxicol Pathol; 2018 Oct; 46(7):735-745. PubMed ID: 30139307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.